What medical experts are saying

"We agree with CETF that preventative approaches have the best chance of alleviating suffering and death from COVID-19 and commend them for supporting these much needed lines of investigation."

Bert Vogelstein

Professor of Oncology Johns Hopkins Medical Institutions

“I strongly support the work CETF is doing. Testing the top antiviral drugs must be our #1 priority. It is critical to raise funds to enable this testing to take place as soon as possible.”

Siddhartha Mukherjee, MD, PhD

Department of Medicine, Division of Hematology/Oncology, Columbia University. Pulitzer Prize Winner

"It's invigorating to see that CETF is working to fund COVID-19 research in a rapid and collaborative manner and focusing their resources on strategies that are likely to have the greatest immediate impact."

Chetan Bettegowda

Professor of Neurosurgery and Oncology Johns Hopkins Medical Institutions

“Finding a safe and effective treatment for patients suffering from COVID-19 is an urgent need and applaud you in your efforts to advance the field.”

Eunjoo Pacifici, PharmD, PhD Chair and Associate Professor

Department of Regulatory and Quality Sciences USC School of Pharmacy

“It’s energizing to see the private sector stepping up in this fight on the COVID-19 virus. Efforts like this can catalyze the research needed to find those treatments that can be safe and effective in saving lives until a vaccine is found that can prevent viral spread. I commend the COVID-19 Early Treatment Fund (CETF) on its efforts to promote promising research.”

Jakub Tolar, MD, PhD,

Dean of the University of Minnesota Medical School and Vice President for Clinical Affairs

These leading medical experts believe repurposing existing drugs should be a top priority

Outpatient clinical trials of our best drug candidates should be prioritized to reduce hospitalizations and safely reopen the world as soon as possible. We should start these trials now.

Bert Vogelstein, Johns Hopkins
David D. Ho, Columbia University
Siddhartha Mukherjee, Columbia University
Mark Sulkowski, Johns Hopkins
Robert Siliciano, Johns Hopkins
Warner Greene, UCSF
Michael Ison, Northwestern University
Scott Friedman, Mount Sinai
Rich D'Aquila, Northwestern
David Boulware, University of Minnesota
Joe Vinetz, Yale School of Medicine
Ole Schmeltz Søgaard, Aarhus University, Denmark

The importance of outpatient trials has been documented in several medical journals:

Donate to the
COVID-19 Early Treatment Fund today
Donate